Related Experiment Video
Updated: Mar 6, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma
Elisabeth Höring1,2,3, Arnau Montraveta3, Simon Heine1
1Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany.
Abstract:
Imbalances in the composition of BCL2 family proteins contribute to tumourigenesis and therapy resistance of mantle cell lymphoma (MCL), making these proteins attractive therapy targets. We studied the efficiency of dual targeting the NOXA/MCL1 axis by combining fatty acid synthase inhibitors (NOXA stabilization) with the CDK inhibitor Dinaciclib (MCL1 reduction). This combination synergistically induced apoptosis in cell lines and primary MCL cells and led to almost complete inhibition of tumour progression in a mouse model. Apoptosis was NOXA-dependent and correlated with the NOXA/MCL1 ratio, highlighting the importance of the NOXA/MCL1 balance for effective cell death induction in MCL.
Insights
Combining fatty acid synthase inhibitors and Dinaciclib synergistically targets the NOXA/MCL1 axis, inducing apoptosis and inhibiting mantle cell lymphoma (MCL) progression. This dual-targeting strategy shows promise for MCL therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Imbalances in BCL2 protein family composition drive mantle cell lymphoma (MCL) development and treatment resistance.
- BCL2 family proteins represent promising therapeutic targets in MCL.
Purpose of the Study:
- To investigate the efficacy of dual targeting the NOXA/MCL1 axis in MCL.
- To evaluate the combination of fatty acid synthase (FAS) inhibitors and the CDK inhibitor Dinaciclib for MCL treatment.
Main Methods:
- Utilized cell lines and primary MCL cells for in vitro studies.
- Employed a mouse model to assess in vivo tumor progression.
- Combined FAS inhibitors (for NOXA stabilization) with Dinaciclib (for MCL1 reduction).
Main Results:
- The combination therapy synergistically induced apoptosis in MCL cell lines and primary cells.
- Tumor progression was almost completely inhibited in a mouse model.
- Apoptosis induction was dependent on NOXA and correlated with the NOXA/MCL1 ratio.
Conclusions:
- The NOXA/MCL1 balance is critical for effective apoptosis induction in MCL.
- Dual targeting of the NOXA/MCL1 axis represents a potent therapeutic strategy for mantle cell lymphoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation

